Repository logo
  • English
  • äø­ę–‡
  • Log In
    New user? Click here to register.Have you forgotten your password?
Repository logo
    Communities & Collections
    Research Outputs
    Fundings & Projects
    People
    Organizations
    Statistics
  • English
  • äø­ę–‡
  • Log In
    New user? Click here to register.Have you forgotten your password?
  1. Home
  2. College of Medicine ļ¼é†«å­øé™¢
  3. Institute of Medicineļ¼é†«å­øē ”ē©¶ę‰€
  4. Antirheumatic drugs and the risk of nonalcoholic fatty liver disease in patients with rheumatoid arthritis: A nationwide, population‐based cohort study
 
  • Details
Options

Antirheumatic drugs and the risk of nonalcoholic fatty liver disease in patients with rheumatoid arthritis: A nationwide, population‐based cohort study

Journal
International Journal of Rheumatic Diseases
Journal Volume
27
Journal Issue
1
ISSN
1756-1841
1756-185X
Date Issued
2023-12-11
Author(s)
Chia‐Chu Meng
Der‐Yuan Chen
Yi‐Hsing Chen
Wen‐Nan Huang
Hsin‐Hua Chen
DOI
10.1111/1756-185X.15003
URI
https://scholars.csmu.edu.tw/handle/123456789/4883
Abstract
<jats:title>Abstract</jats:title><jats:sec><jats:title>Objectives</jats:title><jats:p>To assess the association between antirheumatic drugs and of the risk of nonalcoholic fatty liver disease (NAFLD) in a nationwide rheumatoid arthritis (RA) cohort.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>Using claim data from the 2000–2020 National Health Insurance Research Database, we identified 21 457 incident patients with RA from 2002 to 2020 without prior liver diseases. A time‐varying multivariable Cox regression model was applied to estimate for the association of NAFLD with the use of antirheumatic drugs after adjusting potential confounders, show as adjusted hazard ratios (aHRs) with 95% confidence interval (CIs). Subgroup analyses were conducted based on age‐, sex‐, and obesity‐related comorbidities.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Multivariable time‐dependent Cox regression analyses showed that defined daily dose (DDD) of NSAID (aHR, 1.03; 95% CI: 1.02–1.05) and prednisolone equivalent dose >5 mg/day (aHR, 2.39; 95% CI: 1.85–3.09) were risk factors of NAFLD in patients with RA, while prednisolone equivalent dose ≤5 mg/day (aHR of 0.53; 95% CI: 0.40–0.71) and HCQ use (aHR of 0.75; 95% CI: 0.60–0.93) were associated with a decreased risk of NAFLD. In addition, a history of hospitalizations, number of outpatient visits, age, male, and leflunomide use were associated with the development of NAFLD in some subgroups.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>This study reveals that NSAID use and prednisolone equivalent dose >5 mg/day were associated with an increased risk of NAFLD in patients with RA, while the use of HCQ and prednisolone equivalent dose ≤5 mg/day decreased the risk of NAFLD.</jats:p></jats:sec>
SDGs

[SDGs]SDG2

[SDGs]SDG3

Publisher
Wiley
Type
journal-article
Make it your own

DSpace-CRIS can be extensively configured to meet your needs. Decide which information need to be collected and available with fine-grained security. Start updating the theme to match your Institution's web identity.

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science

  • Cookie settings
  • Privacy policy
  • End User Agreement
  • Send Feedback